Piper Sandler downgraded Sage Therapeutics (SAGE) to Neutral from Overweight with a price target of $8.50, down from $9, after the company entered into an agreement for Supernus to acquire it through a tender offer for $8.50 per share in cash plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sarepta suspends Elevidys shipments, Supernus acquires Sage: Morning Buzz
- Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
- Video: Sarepta, Hinge Health among major pre-market movers
- SAGE Therapeutics Announces Merger with Supernus Pharmaceuticals
- Supernus to acquire Sage Therapeutics for $8.50 per share in cash plus CVR